Marketing Gets Another One Wrong (or right for us)

0
Marketing Gets Another One Wrong (or right for us)

It’s been a week since I wrote that the institutional selling in Valeant (VRX:NYSE) would end on Thursday and pent up institutional buyers would show up on Friday. I didn’t expect a 40% move higher, but am not complaining either.

My hunch is that under the hood, Valeant looks a lot more like SunEdison (SUNE:NASDAQ) than Allergan (AGN:NYSE) and I don’t want to stick around to find out the answer. Despite some premium remaining on my puts, I’ve booked them all this morning.

WSJ Techlive: IPO, SPAC Or Direct Listing? The Path To Going Public

investThis year has been a record-breaking year for initial public offerings with companies going public via SPAC mergers, direct listings and standard IPOS. At Techlive this week, Jack Cassel of Nasdaq and A.J. Murphy of Standard Industries joined Willem Marx of The Wall Street Journal and Barron's Group to talk about companies and trends in Read More

This was a very small position, but more than pays for my trip to Nevis (and a few dozen more).

On the flight home from Nevis (who knew that an iPhone took such good pics???)

Nevis 1

On the flight home from Nevis (who knew that an iPhone took such good pics???)

Categories: Current Investments
Positions Mentioned: none

Updated on

No posts to display